{"url_path":"/sec/bkyi/10-k/2026/item-9b","section_key":"item-9b","section_title":"Item 9B ** **OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1019034/0001437749-26-020446-index.html","accession_number":"0001437749-26-020446","cik":"0001019034","ticker":"BKYI","issuer_name":"BIO KEY INTERNATIONAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1019034/0001437749-26-020446-index.html","primary_entity_key":"0001019034","primary_entity_name":"BIO KEY INTERNATIONAL INC"},"word_count":288,"has_tables":true,"body_markdown":"**ITEM 9B.** **OTHER INFORMATION**\n\n \n\nDuring the *three* months ended *December 31, 2025,*none of our directors or “officers” (as defined in Rule *16a*-*1*(f) under the Securities Exchange Act of *1934,* as amended) adopted or terminated a “Rule *10b5*-*1* trading arrangement” or “non-Rule *10b5*-*1* trading arrangement,” as each term is defined in Item *408* of Securities and Exchange Commission Regulation S-K.\n\n \n\nBecause this Annual Report on Form *10*-K is being filed within *four* business days from the date of the reportable event noted below, we have elected to make the following disclosure in this Annual Report on Form *10*-K instead of in a Current Report on Form *8*-K under Item *2.06* - Material Impairments. The following disclosure is intended to satisfy the requirements of Item *2.06* of Form *8*-K.\n\n \n\nOn *June 10, 2026,*in connection with preparing audited financial statements for the fiscal year ended *December 31, 2025,*the Company completed its annual impairment testing of the value of its investment in shares of common stock of Boumarang, Inc. (the “Boumarang Shares”).  The valuation of the Boumarang Shares was based on an independent valuation report prepared by a *third* party which valued the Boumarang Shares at *$5.000,000* as of *December 31, 2025. *The valuation was based in part on the anticipated revenues of Boumarang which have *not* been achieved as of *June 10, 2006. *As a result, the Company determined  to record a *50%* impairment of its investment in Boumarang Shares which resulted in a material charge for impairment of *$2.5* million under U.S. generally accepted accounting principles. This noncash impairment charge is reflected in the Company’s audited financial statements for the fiscal year ended *December 31, 2025.*The Company does *not* anticipate that this charge will result in material future cash expenditures."}